At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 120 enrolled
Drug / intervention
Obicetrapibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Placebo-Controlled, Double-Blind, Randomized, Phase 2 Dose-Finding Study to Evaluate the Effect of Obicetrapib as an Adjunct to High-Intensity Statin Therapy
In Brief
A Phase 2 clinical trial evaluating Obicetrapib for Dyslipidemias and 2 related conditions. Completed, enrolled 120 participants across 19 sites.
Detailed Summary
This study will be a placebo-controlled, double-blind, randomized, phase 2 dose-finding study to evaluate the efficacy, safety, and tolerability of obicetrapib as an adjunct to high-intensity statin therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDyslipidemias, High Cholesterol, Hypercholesterolemia
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedFeb 2021
Enrollment StartFeb 2021
Primary CompletionMay 2021
Study CompletionAug 2021
TodayJul 2026
First PostedFeb 15, 2021
Enrollment StartFeb 18, 2021
Primary CompletionMay 24, 2021
Study CompletionAug 30, 2021
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 5.4 years ago
Interventions
Obicetrapibdrug
tablets